JP6397405B2 - 生物学的に活性なタンパク質を含む医薬品の製造方法および得られる製品 - Google Patents
生物学的に活性なタンパク質を含む医薬品の製造方法および得られる製品 Download PDFInfo
- Publication number
- JP6397405B2 JP6397405B2 JP2015520947A JP2015520947A JP6397405B2 JP 6397405 B2 JP6397405 B2 JP 6397405B2 JP 2015520947 A JP2015520947 A JP 2015520947A JP 2015520947 A JP2015520947 A JP 2015520947A JP 6397405 B2 JP6397405 B2 JP 6397405B2
- Authority
- JP
- Japan
- Prior art keywords
- frozen
- support
- sugar
- drying
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 45
- 102000004169 proteins and genes Human genes 0.000 title claims description 45
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 title claims description 3
- 238000001035 drying Methods 0.000 claims description 60
- 235000000346 sugar Nutrition 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 31
- 230000005855 radiation Effects 0.000 claims description 23
- 230000000670 limiting effect Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 150000008163 sugars Chemical class 0.000 claims description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 13
- 229960004793 sucrose Drugs 0.000 claims description 13
- 239000005720 sucrose Substances 0.000 claims description 11
- 239000011159 matrix material Substances 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 8
- 230000008014 freezing Effects 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000013681 dietary sucrose Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000000859 sublimation Methods 0.000 description 12
- 230000008022 sublimation Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000006260 foam Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000712083 Canine morbillivirus Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 102100038909 Caveolin-2 Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- -1 polytetrafluoroethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/175—Canine distemper virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明の目的を達成するために、生物学的に活性なタンパク質を含む医薬品の製造方法を提供し、該製造方法は、溶媒、生物学的に活性なタンパク質および20%w/w〜60%w/wの非高分子糖を含む水性組成物を準備し、該組成物を凍結し、それにより、溶媒を凍結形態で含む少なくとも1つの凍結物体を形成させ、該凍結物体を、支持体により保持させて乾燥装置内に入れ、ここで該支持体は、支持体の境界の1以上を定める1以上の制限要素を含み、該物体の表面の多くとも30%が該制限要素の1以上に隣接しており、乾燥装置内の圧力を大気圧未満に減少させ、該物体に熱を(典型的には伝導および/または放射により)供与して、物体の凍結溶媒を昇華させ、そして、乾燥物体を得る工程を含む。
製造(生成):更なる使用のために、例えば、実験室における使用に、工場における使用に、中間体生成物として、または消費者(最終使用者)による使用のために提供すること。製造(生成)は、生産、すなわち、より大量の同一生成物を得るために、制御された反復可能な様態での製造を含む。
1つの実施形態においては、凍結溶媒を48時間以内に昇華させる。熱流は、好ましくは、物体が48時間以内に乾燥されるように選択される。これは、生物学的に活性なタンパク質が比較的高い乾燥温度に付される時間を有意に短縮する。驚くべきことに、現在の配置においては、そのような短い乾燥時間は、タンパク質の有意な活性の喪失を伴うことなく得られうる。好ましくは、凍結溶媒は36時間以内、または更には16〜24時間以内に昇華する。生物学的に活性なタンパク質と少なくとも20%w/wの非高分子糖とを含む物体を乾燥させるための先行技術の凍結乾燥法と比較して、これは非常に短い乾燥時間である。
図1は、第1のタイプの支持体、すなわち、ガラスバイアルを図示し、これは、凍結した回転楕円体が充填されており、または支持体内に充填された後で凍結された液体組成物が充填されている。この図は、それぞれ約110μlの約15個の凍結球体(5)が充填された第1ガラスバイアル(1)を示す。この図はまた、1つの凍結ケーク(6)を形成するように凍結された1.5mlの液体組成物が充填された第2ガラスバイアル(1’)を示す。
図2は凍結乾燥装置における乾燥配置を図示する(装置全体は示されていない)。この図は、バイアル1および1’を収容する棚(10)を示す。バイアル1は、凍結球体5が充填されており、バイアル1’は、凍結液のケーク(6)が充填されている。棚は内蔵電気ヒーター(示されていない)により加熱されうる。
図3は凍結乾燥装置における代替的乾燥配置を図示する。この配置においては、加熱棚(10)から実質的に断熱された高架支持体(20)の上にバイアルが置かれている。このようにして、バイアルは、棚(10)において生じた熱の伝導による熱を実質的に全く受けない。バイアルの上に第2加熱棚(10’)が存在し、この棚には黒色コーティング(11)が施されている。この黒色コーティングは、棚が良好な放射源として働いて、バイアルに対して熱放射12(主に赤外光)を放出することをもたらす。
図4は凍結乾燥装置におけるもう1つの代替的乾燥配置を図示する。この配置は2つの棚を使用し、1つの棚は、第1熱源として働く加熱棚10であり、1つの棚は、(図3に示されている配置に対応する、棚10’の下部に放射表面を付与する黒色コーティング11を介して)第2熱源として働く加熱棚10’である。第1棚10の上には、開放容器15および15’が配置されている。容器15には凍結球体(5)の単層が充填されており、第2容器15’には凍結液(6’)が充填されている。
Claims (14)
- ・溶媒、生物学的に活性なタンパク質および20%w/w〜60%w/wの非高分子糖を含む水性組成物を準備し、
・組成物を凍結し、それにより、溶媒を凍結形態で含む少なくとも1つの凍結物体を形成させ、
・凍結物体を、支持体により保持させて乾燥装置内に入れ、ここで、支持体は、支持体の境界の1以上を定める1以上の制限要素を含み、物体の表面の多くとも30%が制限要素の1以上に隣接しており、
・乾燥装置内の圧力を大気圧未満に減少させ、
・物体に熱を供与して、物体の凍結溶媒を昇華させ、そして、乾燥物体を得る工程を含む、生物学的に活性なタンパク質を含む医薬品の製造方法であって、ここで、生物学的に活性なタンパク質は、非高分子糖の固体マトリックス中に分散され、そして、該物体が、50μl又はそれ以上の体積を有する回転楕円体である、方法。 - 凍結溶媒が48時間以内に昇華する、請求項1記載の製造方法。
- 凍結溶媒が36時間以内に昇華する、請求項2記載の製造方法。
- 凍結溶媒が16〜24時間で昇華する、請求項3記載の製造方法。
- 物体の表面の多くとも20%が支持体の制限要素の1以上に隣接している、請求項1〜4のいずれか1項記載の製造方法。
- 物体の表面の多くとも10%が支持体の制限要素の1以上に隣接している、請求項5記載の製造方法。
- 支持体の制限要素が床であり、物体がこの床上に配置され、放射が該床へと自由に通過することが可能となるように支持体が開放されており、支持体の上方の乾燥装置内に存在する放射源から熱放射を放出させて凍結物体に到達させることにより、熱の少なくとも一部を供与する、請求項1〜6のいずれか1項記載の製造方法。
- 支持体の制限要素が床であり、物体がこの床上に配置され、放射が床へと自由に通過することが可能となるように支持体が開放されており、支持体の上方の乾燥装置内に存在する放射源から熱放射を放出させて物体に到達させることと、凍結物体に隣接している制限要素を介した熱の伝導とを組合せることにより熱を供与する、請求項1〜6のいずれか1項記載の製造方法。
- 水性組成物中の糖の量が、20〜55%w/w、20〜50%w/w、20〜45%w/w、25〜45%w/w、25〜40%w/w、25〜35%w/wおよび27〜30%w/wの範囲からなる群から選択される、請求項1〜8のいずれか1項記載の製造方法。
- 糖が単量体および/または二量体分子を含む、請求項1〜9のいずれか1項記載の製造方法。
- 糖がグルコース、ガラクトース、マルトース、スクロース、トレハロース、フルクトース、ラクトース、サッカロース、マンニトール、ソルビトールおよび/またはキシリトールを含む、請求項10記載の製造方法。
- 乾燥物体内の残留水分含量が2%w/w未満である、請求項1〜11のいずれか1項記載の製造方法。
- 非高分子糖の固体マトリックス中に分散された生物学的に活性なタンパク質を含む50〜1000μlの体積を有する実質的に均一な凍結乾燥物体であって、該物体が約21〜72%w/vの該糖を含むことを特徴とする、物体であって、該物体は、請求項1〜12のいずれか一項に記載の方法により調製される乾燥物体である、凍結乾燥物体。
- 請求項13に記載の実質的に均一な凍結乾燥物体を含む、医薬製品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261669797P | 2012-07-10 | 2012-07-10 | |
US61/669,797 | 2012-07-10 | ||
PCT/EP2013/064422 WO2014009328A1 (en) | 2012-07-10 | 2013-07-09 | A method to produce a medicinal product comprising a biologically active protein and the resulting product |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015522055A JP2015522055A (ja) | 2015-08-03 |
JP6397405B2 true JP6397405B2 (ja) | 2018-09-26 |
Family
ID=48747587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015520947A Active JP6397405B2 (ja) | 2012-07-10 | 2013-07-09 | 生物学的に活性なタンパク質を含む医薬品の製造方法および得られる製品 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20140017318A1 (ja) |
EP (1) | EP2872179B1 (ja) |
JP (1) | JP6397405B2 (ja) |
CN (1) | CN104428004B (ja) |
AU (1) | AU2013289307B2 (ja) |
BR (1) | BR112015000404B1 (ja) |
CA (1) | CA2878353C (ja) |
ES (1) | ES2620084T3 (ja) |
MX (1) | MX356562B (ja) |
RU (1) | RU2663581C2 (ja) |
WO (1) | WO2014009328A1 (ja) |
ZA (1) | ZA201409367B (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
EP3057978B1 (en) | 2013-10-16 | 2022-09-14 | Merck Sharp & Dohme LLC | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
US9782470B2 (en) | 2013-10-16 | 2017-10-10 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
CA2926696A1 (en) | 2013-10-16 | 2015-04-23 | Merck Sharp & Dohme Corp | Thermostable respiratory synctial virus (rsv) vaccine compositions |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
FR3024780B1 (fr) * | 2014-08-07 | 2018-11-30 | Bertin Pharma | Reactif pret a l'emploi |
WO2017066134A1 (en) * | 2015-10-16 | 2017-04-20 | Merck Sharp & Dohme Corp. | Processes for preparing formulations for gastrointestinal-targeted therapies |
EP4078055A4 (en) * | 2019-12-16 | 2024-03-27 | Northwestern University | FREEZE DRIED REAGENTS |
CN114159555A (zh) * | 2021-12-08 | 2022-03-11 | 江西赛基生物技术有限公司 | 抗原蛋白冻干小球及其制备方法 |
CN117159480B (zh) * | 2023-11-01 | 2024-03-01 | 江西赛基生物技术有限公司 | 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133001A (en) * | 1959-11-26 | 1964-05-12 | Muset Pedro Puig | Stabilization of enzymes |
JPS589688A (ja) * | 1981-07-06 | 1983-01-20 | Toyobo Co Ltd | 安定な酵素組成物 |
US5443959A (en) * | 1992-09-09 | 1995-08-22 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
US5593824A (en) * | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
US5565318A (en) | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
AU716785B2 (en) * | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
JP2001168002A (ja) * | 1999-12-06 | 2001-06-22 | Mitsubishi Electric Corp | 半導体装置およびその製造に用いるフォトマスクならびにその重ね合わせ精度向上方法 |
AU2001276737A1 (en) * | 2000-08-04 | 2002-02-18 | Chugai Seiyaku Kabushiki Kaisha | Protein injection preparations |
AU2003234090A1 (en) * | 2002-04-11 | 2003-10-27 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
US6931888B2 (en) * | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
US7129778B2 (en) * | 2003-07-23 | 2006-10-31 | Northrop Grumman Corporation | Digital cross cancellation system |
GB2404880B (en) * | 2003-07-25 | 2005-10-12 | Ultrasound Brewery | Ultrasonic solution separator |
US7435422B2 (en) * | 2004-01-15 | 2008-10-14 | Intervet International B.V. | Non-animal origin stabilizers and processes for producing the same |
RU2283603C1 (ru) * | 2005-02-21 | 2006-09-20 | Калининградский государственный технический университет | Способ сублимационной сушки пищевых продуктов |
US20070259348A1 (en) * | 2005-05-03 | 2007-11-08 | Handylab, Inc. | Lyophilized pellets |
US20070025934A1 (en) * | 2005-07-29 | 2007-02-01 | L'oreal | Nail varnish containing a polyoxyalkylene-chain polymer |
EP2004144A1 (en) * | 2005-12-02 | 2008-12-24 | Stichting Katholieke Universiteit | Method for obtaining hollow particles |
RU2464973C2 (ru) * | 2006-01-24 | 2012-10-27 | НексБио, Инк. | Технология изготовления макромолекулярных микросфер |
WO2008107908A1 (en) * | 2007-03-05 | 2008-09-12 | Cadila Healthcare Limited | Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant |
CN101755044B (zh) | 2007-05-18 | 2014-06-11 | 米迪缪尼有限公司 | 通过冻干泡沫保存生物活性材料 |
TWI436789B (zh) * | 2008-01-21 | 2014-05-11 | Intervet Int Bv | 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包 |
EP2589392B1 (en) * | 2008-03-05 | 2016-11-30 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
RU2371916C1 (ru) * | 2008-06-04 | 2009-11-10 | Государственное научное учреждение ордена "Знак Почета" Научно-исследовательский институт сельского хозяйства Крайнего Севера Сибирского отделения Российской академии сельскохозяйственных наук (ГНУ НИИСХ КС СО Россельхозакадемии) | Способ консервирования пантов северных оленей с использованием инфракрасного излучения |
US8405558B2 (en) * | 2008-06-19 | 2013-03-26 | Sharp Kabushiki Kaisha | Wireless device |
EP2320183B1 (en) * | 2008-07-10 | 2016-08-24 | Ulvac, Inc. | Freeze-drying device |
TWI468157B (zh) * | 2009-04-29 | 2015-01-11 | Intervet Int Bv | 形成錠劑的方法,進行該方法的系統及包含該錠劑的包裝物 |
TWI471127B (zh) * | 2009-04-29 | 2015-02-01 | Intervet Int Bv | 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物 |
US8357401B2 (en) * | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
-
2013
- 2013-07-08 US US13/936,500 patent/US20140017318A1/en not_active Abandoned
- 2013-07-09 RU RU2015104159A patent/RU2663581C2/ru active
- 2013-07-09 ES ES13734433.9T patent/ES2620084T3/es active Active
- 2013-07-09 CN CN201380036052.8A patent/CN104428004B/zh active Active
- 2013-07-09 JP JP2015520947A patent/JP6397405B2/ja active Active
- 2013-07-09 MX MX2015000434A patent/MX356562B/es active IP Right Grant
- 2013-07-09 WO PCT/EP2013/064422 patent/WO2014009328A1/en active Application Filing
- 2013-07-09 EP EP13734433.9A patent/EP2872179B1/en active Active
- 2013-07-09 US US14/413,341 patent/US20150140102A1/en not_active Abandoned
- 2013-07-09 BR BR112015000404-0A patent/BR112015000404B1/pt active IP Right Grant
- 2013-07-09 CA CA2878353A patent/CA2878353C/en active Active
- 2013-07-09 AU AU2013289307A patent/AU2013289307B2/en active Active
-
2014
- 2014-12-18 ZA ZA2014/09367A patent/ZA201409367B/en unknown
-
2018
- 2018-05-17 US US15/982,287 patent/US20180369146A1/en not_active Abandoned
-
2020
- 2020-07-01 US US16/918,611 patent/US20200390712A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180369146A1 (en) | 2018-12-27 |
ZA201409367B (en) | 2015-11-25 |
AU2013289307B2 (en) | 2017-12-14 |
US20140017318A1 (en) | 2014-01-16 |
EP2872179B1 (en) | 2017-01-11 |
WO2014009328A1 (en) | 2014-01-16 |
ES2620084T3 (es) | 2017-06-27 |
CA2878353C (en) | 2021-04-20 |
AU2013289307A1 (en) | 2015-01-22 |
US20200390712A1 (en) | 2020-12-17 |
CN104428004B (zh) | 2021-03-12 |
MX2015000434A (es) | 2015-03-12 |
CA2878353A1 (en) | 2014-01-16 |
RU2663581C2 (ru) | 2018-08-07 |
CN104428004A (zh) | 2015-03-18 |
JP2015522055A (ja) | 2015-08-03 |
RU2015104159A (ru) | 2016-08-27 |
EP2872179A1 (en) | 2015-05-20 |
BR112015000404B1 (pt) | 2022-08-09 |
MX356562B (es) | 2018-06-04 |
BR112015000404A2 (pt) | 2017-06-27 |
US20150140102A1 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6397405B2 (ja) | 生物学的に活性なタンパク質を含む医薬品の製造方法および得られる製品 | |
US8516714B2 (en) | Method for lyophilising particles having a pharmaceutical compound contained therein and a pharmaceutical pack containing such particles | |
CN101755044B (zh) | 通过冻干泡沫保存生物活性材料 | |
Rexroad et al. | Lyophilization and the thermostability of vaccines | |
BRPI1013809B1 (pt) | composição em pó seca, está'vel, compreendendo microorganismos biologicamente ativos e/ou materiais bioativos e métodos de fabricaçâo da mesma | |
JP2005538939A (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
CA2926696A1 (en) | Thermostable respiratory synctial virus (rsv) vaccine compositions | |
WO2001037804A2 (en) | Preservation and formulation of bioactive materials | |
Pandya et al. | Letters in Applied NanoBioScience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180723 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180831 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6397405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |